235 related articles for article (PubMed ID: 35398462)
1. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW
J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462
[TBL] [Abstract][Full Text] [Related]
2. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
[TBL] [Abstract][Full Text] [Related]
3. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
[TBL] [Abstract][Full Text] [Related]
4. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
[TBL] [Abstract][Full Text] [Related]
5. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract][Full Text] [Related]
7. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
Yoo S; Kim JY; Lim YS; Han S; Choi J
J Hepatol; 2022 Oct; 77(4):939-946. PubMed ID: 35643206
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
Choi J; Yoo S; Lim YS
Hepatology; 2021 Jun; 73(6):2155-2166. PubMed ID: 33131063
[TBL] [Abstract][Full Text] [Related]
10. CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance.
Lee HW; Yip TC; Wong VW; Lim YS; Chan HL; Ahn SH; Wong GL; Choi J
Aliment Pharmacol Ther; 2024 May; 59(10):1223-1235. PubMed ID: 38425096
[TBL] [Abstract][Full Text] [Related]
11. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
12. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
[TBL] [Abstract][Full Text] [Related]
13. What can we learn from hepatitis B virus clinical cohorts?
Lin CL; Tseng TC; Kao JH
Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
[TBL] [Abstract][Full Text] [Related]
14. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.
Park YM; Lee SG
World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808
[TBL] [Abstract][Full Text] [Related]
16. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
[TBL] [Abstract][Full Text] [Related]
17. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
[TBL] [Abstract][Full Text] [Related]
18. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
Gounder PP; Bulkow LR; Snowball M; Negus S; Spradling PR; Simons BC; McMahon BJ
Aliment Pharmacol Ther; 2016 Jun; 43(11):1197-207. PubMed ID: 27061300
[TBL] [Abstract][Full Text] [Related]
19. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
Li J; Yang HI; Yeh ML; Le MH; Le AK; Yeo YH; Dai CY; Barnett S; Zhang JQ; Huang JF; Trinh HN; Wong C; Wong C; Hoang JK; Cheung R; Yu ML; Nguyen MH
J Infect Dis; 2021 Jul; 224(2):294-302. PubMed ID: 33249474
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Kuang XJ; Jia RR; Huo RR; Yu JJ; Wang JJ; Xiang BD; Li LQ; Peng Z; Zhong JH
J Viral Hepat; 2018 Sep; 25(9):1026-1037. PubMed ID: 29624821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
